Rhumbline Advisers Decreases Position in Cencora, Inc. (NYSE:COR)

Rhumbline Advisers trimmed its position in Cencora, Inc. (NYSE:COR - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 401,068 shares of the company's stock after selling 17,757 shares during the period. Rhumbline Advisers owned 0.21% of Cencora worth $90,112,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Concord Wealth Partners bought a new stake in Cencora during the third quarter valued at $30,000. Householder Group Estate & Retirement Specialist LLC boosted its position in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the last quarter. Kentucky Trust Co bought a new position in shares of Cencora in the fourth quarter worth approximately $33,000. WASHINGTON TRUST Co raised its stake in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in Cencora in the third quarter valued at approximately $41,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at $79,670,111.29. This represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on COR shares. UBS Group boosted their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Robert W. Baird raised their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Wells Fargo & Company upped their price objective on Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Finally, Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $277.90.

Cencora Trading Up 1.6 %

Shares of COR traded up $3.93 during trading hours on Wednesday, reaching $245.37. 1,553,062 shares of the company traded hands, compared to its average volume of 1,511,064. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company's fifty day moving average price is $238.75 and its two-hundred day moving average price is $237.41. The company has a market capitalization of $47.58 billion, a price-to-earnings ratio of 34.90, a price-to-earnings-growth ratio of 1.30 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.